EFFECT ·Filed Jul 13, 2026

INO

INOVIO PHARMACEUTICALS, INC.
BEARISH
Impact 6/10
Horizonweeks Processed2mo ago SEC9999999995-26-002261
IPO/offering going effective
Actionable Insight ▼ Bearish

Monitor for any takedown announcements (prospectus supplements) that would signal immediate dilution. The effective shelf creates ongoing overhang; any offering below current market price would pressure the stock. Key catalyst remains the October 30, 2026 PDUFA date for INO-3107.

DirectionBearish
Confidencelow
Horizonweeks
Latest settled — T+20d
INO ▼ -36.52% at T+20d
SHORT call ✓ call won +36.52% · α vs SPY +39.70% · entry $1.16 → $0.7364
Next anchor: T+60d in 4d
Latest observation: T+56 -7.65% FF3 residual α
Entry anchored
Jul 10, 03:59 PM ET
via exchange tick
T+1d
0.00%
call 0.00% · α +0.36%
$1.16
settled 3mo ago
T+5d
-3.45%
call +3.45% · α +2.66%
$1.12
settled 2mo ago
T+20d
-36.52%
call +36.52% · α +39.70%
$0.7364
settled 8w ago
T+60d
—
call — · α —
—
in 4d

Price Chart

Loading chart...

Executive Summary

Inovio Pharmaceuticals' universal shelf registration (S-3) filed July 2, 2026 has become effective, allowing the company to raise up to $300M through sales of common stock, preferred stock, debt, or warrants. This formalizes the dilution overhang flagged in the prior S-3 analysis, as the company can now take down offerings at any time. Filing document content was unavailable — analysis based on metadata and cross-filing context only.

Key Facts

  • Shelf registration (S-3) declared effective — Inovio can now sell up to $300M in securities
  • Follows S-3 filed July 2, 2026; company has a history of frequent capital raises
  • Market cap is ~$97M, making potential dilution substantial relative to current equity value

Financial Impact

Up to $300M in potential capital raise, representing ~3x current market cap; dilution risk is material

dilutionshare countcash balance

Risk Factors

  • Imminent or gradual equity issuance diluting existing shareholders
  • Stock price pressure from overhang even without immediate takedown
  • Execution risk on pipeline development with limited cash runway

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
67% bullish (9 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

Report based on filing metadata.

8 reports for INO
Performance horizon
83% Hit rate 5 of 6 directional calls best @ T+20▲ +46.23%Jul 2, 2026
Filters
Rows
Reports for INO — sortable, filterable
TypeNow
Jul 31, 2026
9w ago
8-K
BEARISH ★ 6/10
$0.6770 $1.29▼ −90.55%▼ −87.56%$1.18 (−75.04%)
Jul 30, 2026
9w ago
424B5
BEARISH ★ 6/10
$0.6770 $1.29▼ −90.55%▼ −87.56%$1.18 (−75.04%)
Jul 30, 2026
9w ago
Press Release
BEARISH ★ 7/10
$0.6560 $1.26▼ −92.07%▼ −88.11%$1.18 (−80.64%)
Jul 13, 2026
11w ago
EFFECT
BEARISH ★ 6/10
$1.16 $0.7364▲ +36.52%▲ +39.70%$1.18 (−2.16%)
Jul 2, 2026
13w ago
S-3
BEARISH ★ 6/10
$1.22 $0.6560▲ +46.23%▲ +45.81%$1.18 (+2.87%)
Jun 11, 2026
16w ago
Institutional Cluster
NEUTRAL ★ 3/10
$1.10 $1.19▲ +8.18%▲ +6.29%$1.18 (+7.73%)
Apr 6, 2026
25w ago
8-K
BEARISH ★ 6/10
$1.13 $1.14▼ −0.89%▲ +8.10%$1.18 (−4.87%)
Apr 2, 2026
26w ago
424B5
BEARISH ★ 6/10
$1.13 $1.12▲ +0.89%▲ +10.76%$1.18 (−4.87%)
Showing 8 of 8

US Market Status

Market Open — Closes in 3h 40m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access